Oncology Institute Prof Dr Ion Chiricuta Cluj Napoca

Cluj-Napoca, Romania

Oncology Institute Prof Dr Ion Chiricuta Cluj Napoca

Cluj-Napoca, Romania

Time filter

Source Type

Fetica B.,Oncology Institute Prof Dr Ion Chiricuta Cluj Napoca | Fetica B.,University of Medicine and Pharmacy, Cluj-Napoca | Balacescu O.,Oncology Institute Prof Dr Ion Chiricuta Cluj Napoca | Balacescu O.,University of Medicine and Pharmacy, Cluj-Napoca | And 6 more authors.
Cancer Biomarkers | Year: 2014

Nowadays, HER2 testing in breast cancer represents a necessity for both prognostic and therapy. Despite widespread use of immunohistochemistry (IHC) for assessing HER2 status, there are some limitations to identify truly negative or positive HER2 cases. Fluorescence in situ hybridization (FISH) or chromogenic in situ hybridization (CISH) could solve the equivocal HER2 IHC cases but there is no consensus on which is the best method. Consequently, finding a sensitive method for HER2 testing is critical for the management of the disease. In addition, tumor heterogeneity is an important factor which could affect accuracy of molecular diagnostics. Laser capture micro-dissection (LCM) is used to isolate pure cell populations from heterogeneous tumor tissue. The combination between LCM and quantitative polymerase chain reaction (Q-PCR), the gold standard in molecular biology for quantifying gene amplification levels, could define an important tool to improve the molecular diagnostics of HER2 status. In our pilot study we used LCM and Q-PCR to evaluate HER2 gene amplification for invasive breast carcinoma samples. The samples were selected based on HER2 status assessed by IHC and CISH. Our results demonstrated high sensitivity of Q-PCR for assessing HER2 DNA amplification as well as a good concordance between Q-PCR and IHC/CISH assay. © 2014 - IOS Press and the authors.

Loading Oncology Institute Prof Dr Ion Chiricuta Cluj Napoca collaborators
Loading Oncology Institute Prof Dr Ion Chiricuta Cluj Napoca collaborators